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Abstract
Background: Transducin-like enhancer of Split3 (TLE3) serves as a transcriptional corepressor during cell
differentiation and shows multiple roles in different kinds of cancers. Recently, TLE3 together with many other
genes involved in Wnt/β-catenin pathway were detected hyper-methylated in colorectal cancer (CRC). However,
the potential role and the underlying mechanism of TLE3 in CRC progression remain scarce.
Methods: Gene expression profiles were analyzed in The Cancer Genome Atlas (TCGA) microarray dataset of 41
normal colorectal intestine tissues and 465 CRC tissues. Western blot and Real-time Quantitative PCR (RT-qPCR)
were respectively performed to detect protein and mRNA expression in 8 pairs of CRC tissue and matched adjacent
normal mucosa. Immunohistochemistry (IHC) was conducted to evaluate TLE3 protein expression in 105 paraffin-
embedded, archived human CRC tissues from patients, whose survival data were analyzed with Kaplan-Meier
method. In vitro experiments including MTT assay, colony formation assay, and soft agar formation assay were used
to investigate the effects of TLE3 on CRC cell growth and proliferation. Additionally, subcutaneous tumorigenesis
assay was performed in nude mice to confirm the effects of TLE3 in vivo. Furthermore, gene set enrichment
analysis (GSEA) was run to explore potential mechanism of TLE3 in CRC, and then we measured the distribution of
CRC cell cycle phases and apoptosis by flow cytometry, as well as the impacts of TLE3 on MAPK and AKT signaling
pathways by Western blot and RT-qPCR.
Results: TLE3 was significantly down-regulated in 465 CRC tissues compared with 41 normal tissues. Both protein
and mRNA expressions of TLE3 were down-regulated in CRC compared with matched adjacent normal mucosa.
Lower expression of TLE3 was significantly associated with poorer survival of patients with CRC. Besides, knock
down of TLE3 promoted CRC cell growth and proliferation, while overexpression of TLE3 showed suppressive
effects. Furthermore, overexpression of TLE3 caused G1-S phase transition arrest, inhibition of MAPK and AKT
pathways, and up-regulation of p21Cip1/WAF1 and p27Kip1.
Conclusion: This study indicated that TLE3 repressed CRC proliferation partly through inhibition of MAPK and AKT
signaling pathways, suggesting the possibility of TLE3 as a biomarker for CRC prognosis.
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Background
Colorectal cancer (CRC) is one of the most commonly
studied malignancies because of high morbidity and
mortality [1]. CRC carcinogenesis is a multistep progress
involving progressive genetic mutations, epigenetic
adaptation, and immunology aberrances [2–4], which
lead to the complexity of clinical treatment. Although
continuous progresses were obtained in diagnostic and
therapeutic methods, the prognosis and outcome of
CRC patients are far away from satisfaction [5]. Recent
studies intensively focus on personalized therapy that
requires efficient biomarkers capable of assisting early
diagnosis and treatment [6, 7]. However, current bio-
markers of CRC are unmet [8, 9].
Groucho (Gro)/TLE proteins belong to a large family of
transcriptional corepressor that are extensively expressed in
most metazoans. They show high conservation in structure
and function of C-terminal tryptophan–aspartate (WD)-re-
peat domain and N-terminal glutamine-rich (Q) domain
[10]. After direct interaction with DNA-bound transcrip-
tional factors through WD-repeat domain, the Gro/TLE
proteins form into polymer via Q domain with each other
along the chromosome, and then recruit histone deacety-
lases to establish a transcriptionally silenced chromatin
structure [10–12]. This complex exerts long-range repres-
sion on a variety of transcriptional factors including the
members of Hes, Runx, Lcf/Lef, Pax, Six, and c-Myc
families [11, 13]. In this way, the Groucho/TLE proteins
participate in receptor tyrosine kinase (RTK)/Ras/Ral,
mitogen-activated protein kinase (MAPK), Notch, Wnt,
and Hedgehog signaling pathways during processes of
embryonic development, morphogenesis and cell metabol-
ism, as well as neoplastic conditions [10, 14–18].
Transducin-like enhancer of Split 3 (TLE3) is one of
the full-length members of human TLE family [19].
Besides dynamic functions in differentiation and cell
metabolism [15, 20–22], TLE3 emerges attractive prop-
erty in tumorigenesis. It was initially found elevated in
cervical and colonic neoplasms [23, 24]. However,
methylation status analyses of colorectal tumors showed
aberrant methylation in the CpG island of TLE3 when
compared with adjacent normal mucosa [25]. Addition-
ally, altered expression of TLE2 and TLE3 were associated
with high-grade meningioma [26], and the alternatively
spliced isoforms of TLE3 were detected upregulated in
prostate tumor [27, 28]. TLE3 was indifferent in leukemia,
although other TLE proteins were observed coordinating
with FOXG1 to promote B-lineage leukemia of positive
E2A-HLF oncoprotein [29]. Interestingly, several studies
proposed TLE3 as a potential marker of taxane respon-
siveness in the treatment of ovarian carcinoma and breast
cancer [30, 31], but the most recent NCIC CTG MA.21
clinical trial repudiated TLE3 to be a valuable marker for
taxane sensitivity in breast cancer treatment [32]. In
short, these findings revealed the erratic role of TLE3
in human cancers. Further investigation of TLE3’s
pathological characteristics and clinical application in
CRC will be of great significance.
Here, we sought to explore the expression pattern and
potential role of TLE3 in the progression of CRC. Our
study showed that TLE3 expression was significantly down-
regulated in CRC tissue than matched adjacent normal mu-
cosa. Lower expression level of TLE3 was associated with
poorer outcome of CRC patients. Furthermore, TLE3 could
arrested cell cycle progression and suppressed cell prolifera-
tion as well as tumor growth in CRC partially through in-
hibition of MAPK and AKT pathways.
Methods
Patients and specimens
A total of 105 pathological specimens were obtained
from colon cancer patients between 2009 and 2014 at
the Department of Pathology, Nanfang Hospital Southern
Medical University. Medical records of these patients
provided information of gender, age, and following essen-
tial factors: tumor pathological characteristics, pathologic
stage, T stage, Dukes stage, metastases of lymph node, and
distant metastasis. The 8 pairs of fresh biopsies collected
from CRC and their matched noncancerous mucosa tis-
sue were obtained from the operation room of Nanfang
Hospital. The fresh biopsies were stored in liquid nitrogen
before usage. Approval was obtained from the Southern
Medical University Institutional Board (Guangzhou, China)
for the use of clinical materials for research purposes. All
samples were collected and analyzed with the prior written,
informed consent of the patients.
Cell cultures
The human CRC cell lines SW480, Ls174t, HCT15 and
SW620 were purchased from American Type Culture
Collection. SW620 were cultured in DMEM medium
(Gibco) supplemented with 10 % fetal bovine serum (FBS)
(PAA Laboratories, Pasching, Austria). Ls174t, HCT15
and SW480 were cultured in RPMI 1640 medium (Gibco)
with 10 % FBS. Dissolved by DMSO, ERK inhibitor
GDC0994 (50 μM) and AKT inhibitor PF04691502
(10 μM) (Selleck Chemicals, USA) were used to inhibit
the activation of MAPK and AKT pathways, respectively.
Cells were cultured at 37 °C with 5 % CO2.
Plasmids
The full-length TLE3 was amplified by PCR and cloned
into pBabe (Addgene, Inc., Cambridge, MA, USA). The
human short hairpin RNA (shRNA) sequences specific-
ally targeting TLE3 (TLE3 shRNA#1: 5′-CCACACG
TTTGCAACCCAA-3′; TLE3 shRNA#2: 5-CCTCCT
GGTATCTGAACCA-3′) were cloned into pSuper-
retroneo (Oligo-Engine, Seattle, WA, USA).
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RNA isolation, reverse transcription (RT) and Real-time
Quantitative PCR (RT-qPCR)
Total RNA from cultured cells and CRC tissues was iso-
lated using the mirVana miRNA Isolation Kit (Ambion)
according to the manufacturer’s instruction. The cDNA
was then synthesized from total RNA using the Taqman
miRNA reverse transcription kit (Applied Biosystems,
Foster City, CA, USA). RT-qPCR was performed with
the Applied Biosystems 7500 Sequence Detection sys-
tem, using iQ™ SYBR Green Supermix (BioRad Labora-
tories, Hercules, CA, USA). The data were normalized
to the geometric mean of housekeeping gene GAPDH
values and calculated as 2−ΔΔCT method. Sequences of
the primers for RT-qPCR are summarized in Additional
file 1: Table S1.
Western blot
We carried out western blot as previously described
[33], using anti-TLE3 (Abcam, Cambridge, MA, USA),
anti-FOXO3, anti-Akt, anti-GSK-3β, anti-ERK, anti-p21,
anti-p27, anti-p-FOXO3, anti-p-Akt, anti-p-GSK-3β and
anti-p-ERK (Bioworld Technology, St. Louis Park, MN,
USA) to detect the corresponding proteins. Anti-α-
Tubulin monoclonal antibody (Sigma, St. Louis, MO,
USA) served as a loading control.
Immunohistochemistry
Immunohistochemistry (IHC) staining and scoring were
performed as previously described [33]. Ki-67 detected
by anti-Ki-67 (Abcam, Cambridge, MA, USA) repre-
sented the proliferation index.
MTT assay
Cells were incubated for 24 h at 37 °C after the cells
were trypsinized and plated on 96-well plates (1 × 103).
Then 20 μl of 5 g/L MTT (3-(4, 5-dimethylthiazol-z-yl)-
2, 5-diphenyltetrazolium bromide, Sigma, St. Louis, MO,
USA) was added and mixed into each well and incubated
at 37 °C. After 4 h, the MTT-medium mixture was
removed and 150 μl dimethyl sulphoxide (DMSO,
Sigma, St. Louis, MO, USA) were added into the wells.
The absorbance value was measured at 490 nm with a
Microplate Autoreader (Bio-Rad, Hercules, CA, USA).
Three dependent experiment was repeated. Data were
presented as the mean ± SD.
Colony formation assay
Cells (200 cells/well) were trypsinized and plated on 6-
well plates, and then cultured in medium with 10 % FBS
for 2 weeks. The colonies were fixed with 4 % parafor-
maldehyde for 5 min and stained with 1 % crystal violet
for 30 s. Colonies of more than 50 cells were counted.
The experiment was repeated for 3 times independently.
Data were presented as the mean ± SD.
Soft agar assay
60 mm plates were covered with a layer of 0.66 % agar
in medium supplemented with 20 % FBS. Cells (1 × 104)
were seeded on the top of agar layer and cultured in
RPMI 1640 supplemented with 10 % FBS with 0.3 %
agarose. The cells were incubated with 5 % CO2 at 37 °C.
After 2 to 3 weeks, the number of cell colony were
counted under microscope and cell colonies were photo-
graphed in 100 × view. Colonies of more than 50 cells
were counted. The experiment was repeated for 3 times
independently, each cell line respectively. Data were pre-
sented as the mean ± SD.
Cell cycle analysis
Cell cycle distribution was examined by measuring the
cellular DNA content using flow cytometry. Cells at 80–
90 % confluence were incubated for 36 h in the RPMI-
1640 medium containing 0.5 % FBS, then released
through culturing back in RPMI-1640 medium with
10 % FBS for 12 h. 1 × 106 cells were collected and fixed
with 70 % cold ethanol. After treated with RNase A
(10 μg/mL) for 30 min at 37 °C, the cells were resus-
pended in 0.5 mL propidium iodide (PI) solution (50 μg/
mL in 0.1 % sodium citrate with 0.1 % NP-40). Cell cycle
distribution was analyzed by FACScan cytometry (Becton-
Dickinson, San Jose, CA, USA).
Tumorigenesis assay
Cells were trypsinized and then suspended with serum-
free medium. 200 μl cell suspension (2 × 106 cells) was
subcutaneously injected into 4-week-old Balb/Cathymic
nude mice (nu/nu) obtained from the Animal Center of
Southern Medical University, Guangzhou, Guangdong
Province, China. All the animals were housed and main-
tained under specific pathogen-free conditions, and all
experiments were approved by the Use Committee for
Animal Care and performed in accordance with institu-
tional guidelines. Tumor volumes were measured on the
indicated days. Tumor size was measured by a slide
caliper and tumor volume was determined by the for-
mula 0.44 × A × B2 (A indicates tumor base diameter one
direction and B the corresponding perpendicular value).
The tumors were fixed and 4 μm sections were cut and
stained with haematoxylin and eosin according to stand-
ard protocols. Sections were further under IHC staining
using antibody against Ki-67.
Statistical analysis
All statistical analyses were carried out using SPSS
version 19.0 for Windows (IBM, Armonk, NY, USA).
The two-tailed Student’s t-test was used to compare the
intergroup. Survival data were analyzed with Kaplan-
Meier method and were compared using the log-rank
test. p < 0.05 was considered statistically significant.
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Results
Down-regulation of TLE3 was associated with advanced
progression and poor survival of human CRC
In order to identify deregulated genes involved in the
progression of CRC, gene expression profiles were
analyzed in The Cancer Genome Atlas (TCGA) micro-
array datasets. The analyses showed that TLE3 was
significantly down-regulated in 465 CRC tissues com-
pared to 41 normal tissues (Fig. 1a and b). Consistent
with this finding, Western blot and real-time PCR ana-
lyses showed that TLE3 expression was significantly
down-regulated in eight CRC tissues compared with ad-
jacent normal intestine epithelial tissues (Fig. 1c and d).
Furthermore, TLE3 protein expression was detected by
immunohistochemistry (IHC) in 105 paraffin-embedded,
archived human CRC tissues. TLE3 protein expression
was quite abundant in adenoma as well as normal tissue,
whereas it was markedly decreased in adenocarcinoma
(Fig. 1e). Kaplan-Meier survival analysis showed that
CRC patients with lower level of TLE3 protein expression
had a poorer prognosis (Fig. 1f). These results suggest that
TLE3 down-regulation is significantly associated with
advanced progression of human CRC.
Overexpression of TLE3 repressed the proliferation and
tumorigenesis of human CRC cells
To investigate the potential role of TLE3 in the progres-
sion of human CRC, stable CRC cell lines SW480 and
Ls174t of TLE3 overexpression were established (Fig. 2a).
In comparison with control cells, the proliferation of
Fig. 1 Evaluation of TLE3 expression in CRC cell lines and primary human CRC. a Analyses of TLE3 expression in normal colorectal intestines (n = 41)
and colorectal tumors (n = 465) in The Cancer Genome Atlas (TCGA) microarray dataset. b Analyses of TLE3 expression in 41 pairs of tissues of normal
colorectal intestines and colorectal tumors in TCGA microarray dataset. c Expression of TLE3 protein in 8 primary human CRC tissue (T)
and the adjacent normal tissue (N) paired from the same patient by Western blot. d Real-time PCR was used to quantify average N/T
ratios of TLE3 mRNA expression. e Representative images of TLE3 protein expression in normal colorectal epithelia, adenoma and adenocarcinoma
by IHC. TLE3 was positively detected in both adenoma and their adjacent normal tissue (middle and left), whereas there was little detection in
adenocarcinoma (right). f Influence of TLE3 expression on overall survival by Kaplan-Meier analysis in 105 patients with CRC. p < 0.05 The
expression levels of protein or mRNA were normalized with α-Tubulin or GAPDH, respectively. Error bars represent mean ± SD calculated
from 3 independent experiments
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SW480 and Ls174t cells was inhibited by TLE3 overex-
pression as determined by MTT and colony formation
assays (Fig. 2b and c). Anchorage-independent growth
activity was examined using soft agar formation assays,
whose results showed that TLE3 overexpression also
repressed the proliferation of SW480 and Ls174t cells in
soft agar, as both the number and size of colonies were
decreased in comparison with control cells (Fig. 2d). To
confirm this effect in vivo, tumorigenesis assays by
subcutaneous injection were performed in nude mice.
The TLE3 overexpression group exhibited remarkably
slower tumor growth and smaller tumor volume in
comparison with the control group (Fig. 2e, n = 6). In
addition to the difference of tumor volume, much lower
Ki-67 index was found in tumors formed by TLE3 over-
expression group than that in the control group, as
detected by IHC analysis of Ki-67 (Fig. 2f ).
Knock-down of TLE3 promoted the proliferation and
tumorigenesis of human CRC cells
To further confirm the role of TLE3 in human CRC cells
proliferation, endogenous expression of TLE3 in HCT15
and SW620 was knocked down by specific shRNAs
(Fig. 3a). MTT and colony formation assays indicated
that knock-down of TLE3 expression obviously pro-
moted the cell growth of HCT15 and SW620 cells in
comparison with control cells (Fig. 3b and c). Besides,
the number and size of colonies in soft agar assays were
Fig. 2 Overexpression of TLE3 repressed the proliferation and tumorigenesis of human CRC cells. a Overexpression of TLE3 in SW480 and Ls174t
cells. α-Tubulin was used as a loading control. b Overexpression of TLE3 repressed cell proliferation of SW480 and Ls174t cells by MTT assays.
c Overexpression of TLE3 repressed cell proliferation of SW480 and Ls174t cells by colony formation assays. d Overexpression of TLE3 repressed
anchorage-independent growth ability of SW480 and Ls174t cells as determined by soft agar assays. Colonies containing more than 50 cells were
scored. e Tumorigenesis assay by subcutaneous injection of SW480/vector or SW480/TLE3 cells in nude mice (n = 6/group). Tumor volumes were
measured on the indicated days. Data points are the mean tumor volumes ± SD. p < 0.05. f The sections of tumor were under H&E staining or
subjected to IHC staining using an antibody against Ki-67. Error bars represent the mean ± SD of 3 independent experiments. * p < 0.05
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significantly increased in TLE3-silenced HCT15 and
SW620 cells in comparison with control cells (Fig. 3d). Fur-
thermore, knockdown of endogenous TLE3 expression in
SW620 cells led to noteworthy promotion of tumor growth
and volume in the tumorigenesis assays by subcutaneous
injection in nude mice, confirming the suppressive effect of
TLE3 on CRC proliferation in vivo (Fig. 3e; n = 6). In con-
trast to tumors of TLE3 overexpression, Ki-67 index was
found much higher in tumors of TLE3 knock-down in
comparison with control cell-based tumor (Fig. 3f).
TLE3 caused cell cycle G1-S phase transition arrest in
human CRC cell
To explore the possible mechanism by which TLE3 reg-
ulates the proliferation of human CRC cells, we analyzed
TLE3 RNA expression levels based on TCGA COAD
RNA Seq dataset and cycling gene signatures from the
online Gene Set Database of the gene set enrichment
analysis (GSEA) [34]. We observed that TLE3 expression
was negatively correlated with genes related to cell cycle
and G1-S transition (Additional file 2: Figure S1a and b).
Furthermore, flow cytometry was performed to measure
the distribution of cell cycle phases. Compared with con-
trol cells, the percentage of G1-phase cells increased and
S-phase decreased significantly in the SW480 cells with
TLE3 overexpressing (27.14 vs 41.55 %, p < 0.05, and
49.47 vs 34.02 %, p < 0.05, respectively) (Fig. 4a and
Additional file 3: Figure S2a). Another cell line Ls174t of
TLE3 overexpression showed the same results (29.38 vs
51.22 %, p < 0.05 and 52.67 vs 41.38 %, p < 0.05, respect-
ively) (Fig. 4a and Additional file 3: Figure S2a). On the
contrary, decrease in the percentage of G1-phase cells
Fig. 3 Knock-down of TLE3 promoted the proliferation and tumorigenesis of human CRC cells. a RNAi-silencing of TLE3 in shRNA-transduced
stable HCT15 and SW620 cells. α-Tubulin was used as a loading control. b Knock-down of TLE3 promoted cell proliferation of HCT15 and SW620
cells by MTT assays. c Knock-down of TLE3 promoted cell proliferation of HCT15 and SW620 cells by colony formation assays. d Knock-down of
TLE3 promoted anchorage independent growth ability of HCT15 and SW620 cells as determined by soft agar assays. Colonies containing more
than 50 cells were scored. e Tumorigenesis assay by subcutaneous injection of SW620/Scr and SW620/sh-1 cells in nude mice (n = 6/group). Tumor
volumes were measured on the indicated days. Data points are the mean tumor volumes ± SD. f The sections of tumor were under H&E staining or
subjected to IHC staining using an antibody against Ki-67. Error bars represent the mean ± SD of 3 independent experiments. * p < 0.05
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and increase in the percentage of S-phase were observed
after endogenous TLE3 in HCT15 and SW620 cells was
knocked down. The percentage of S-phase cells in
HCT15 and SW620 cells of TLE3 knock-down were
significantly more than that in HCT15 and SW620 cells
of control group (40.35 vs 50.88 %, p < 0.05 and 29.49 vs
39.88 %, p < 0.05, respectively) (Fig. 4b and Additional
file 3: Figure S2b). Moreover, TLE3 overexpressing
significantly increased the percentage of apoptotic cells
in SW480 and Ls174t cells, whereas knockdown of
TLE3 in SW620 and HCT15 cells decreased the number
of apoptotic cells (Fig. 4c and d, Additional file 3: Figure
S2c and d). Taken together, these results demonstrate
that TLE3 inhibits cell cycle progression and promotes
cell death in CRC cells.
TLE3 suppressed CRC partly through inhibition of MAPK
and AKT signaling pathways
The GSEA analysis based on TCGA COAD RNA expres-
sion dataset also revealed that TLE3 level was negatively
correlated with AKT activity (Additional file 4: Figure S3),
indicating that TLE3 might inhibit the activation of AKT
signaling pathway. Moreover, Western blot showed that the
levels of phosphorylated FOXO3, GSK, ERK and AKT were
decreased in SW480 and Ls174t cells with TLE3 overex-
pressing, whereas increased in HCT15 and SW620 cells
with TLE3 knocking down in comparison with control cells
(Fig. 5a). Since TLE3 significantly inhibited the G1-S phase
transition as shown above, we then detected the cyclin-
dependent kinases inhibitor proteins p21Cip1/WAF1 (p21)
and p27Kip1 (p27) that are responsible for this transition
[35, 36]. Results showed that p21 and p27 were upregulated
in SW480 and Ls174t cells with TLE3 overexpressing
(Fig. 5a), whereas they were down-regulated in HCT15 and
SW620 cells with TLE3 knocking down (Fig. 5a). Addition-
ally, transcriptional levels of p21 and p27 were also regu-
lated by TLE3 (Additional file 5: Figure S4 a, b, c and d).
To investigate whether the alterations of p21 and p27
were caused by activation of the MAPK or AKT path-
ways, SW620 cells with TLE3 knocking down were
Fig. 4 TLE3 inhibited cell cycle progression of human CRC cell. a, b Representative figures depicting cell cycle profiles of indicated cells. Cells
were stained with PI and analyzed by flow cytometry. c, d Flow cytometry of annexin V and PI-labelled CRC cells indicating apoptosis
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treated with an ERK inhibitor (GDC0994)[37] or AKT
inhibitor (PF04691502)[38]. Figure 5b showed that the
expression levels of phosphorylated ERK and AKT were
significantly reduced by GDC0994 and PF04691502 in
SW620 cells, respectively. Notably, the expression of p21
and p27 were rescued by treatment with the ERK or
AKT inhibitors compared to control cells treated with
DMSO (Fig. 5b).
To further confirm that TLE3 represses proliferation
by inhibiting the MAPK and AKT pathways, the growth
ability of SW620 cells with TLE3 knocking down after
treatment with GDC0994 or PF04691502 were exam-
ined. MTT assay, colony formation assay and soft agar
assay showed that the growth of SW620 cells were
significantly compromised by treatment with the ERK or
AKT inhibitors compared to control cells treated with
DMSO (Fig. 5c, d and e).
Collectively, these results indicate that TLE3 represses
the proliferation of CRC cells partly through inhibition
of MAPK and AKT signaling pathways and activation
of p21 and p27.
Discussion
Although TLE3 gene was detected hyper-methylated in
CRC [25], our study firstly reported the down-regulation
of TLE3 on both protein and mRNA levels. Results
revealed that low expression of TLE3 in CRC was
significantly correlated with advanced progression and
poor survival of patients. In addition, TLE3 expression
was observed negatively associated with CRC growth
both in vitro and in vivo. However, whether TLE3 could
be used as a valuable biomarker for CRC prognosis
needs further investigation.
The TLE family show structural redundancy [19] but
play multiple roles during tumorigenesis. For instance,
TLE1 coordinated with Qin to promote cell growth and
agar colony formation in chicken embryo fibroblasts
[39]. TLE2 was discovered to bind with replication and
Fig. 5 TLE3 regulated p21 and p27 through the MAPK and AKT signaling pathways in CRC cells. a Western blot analyses of the expression of p-FOXO3a,
total FOXO3a, phosphorylated GSK, total GSK, phosphorylated ERK, total ERK, phosphorylated AKT, total AKT, p21Cip1/WAF1 and p27Kip1 proteins in
indicated human CRC cell lines. b SW620 cells with TLE3 knocking down were treated with the AKT inhibitor PF04691502 (10 μM), the ERK inhibitor
GDC0994 (50 μM) or DMSO for 24 h, then harvested to examine the expression levels of the indicated proteins by western blot. c, d and e Proliferation
ability of SW620 cells with TLE3 knocking down was determined by MTT assay (c), colony formation assay (d) and soft agar assay (e) after treatment with
GDC0994, PF04691502 or DMSO. Error bars represent mean ± SD from 3 independent experiments. * p< 0.05
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transcription activator (RTA) and thus inhibited RTA-
mediated replication and transactivation that was impli-
cated with Kaposi’s sarcoma-associated herpesvirus [40].
TLE1 and TLE4 served as a tumor suppressor gene in
acute myeloid leukemia [41, 42], while it turned to be
oncogenes in lung cancer and colorectal cancer, respect-
ively [43–45]. Another member of TLE family, the TLE3
also performs various roles in cancers, especially in
clinical treatments containing taxane therapy as
mentioned above. On the one hand, TLE3 was found
elevated in cervical neoplasms [23, 24], high-grade
meningiomas [26], and prostate tumor [27, 28]. On the
other hand, high expression of TLE3 was associated favor-
able responses to taxane-containing therapies in ovarian
carcinoma [31] but not in breast cancer [32] and angiosar-
coma [46]. Noteworthy, Zagouras P et al. reported that
TLE family proteins were up-regulated in colonic adeno-
carcinoma as detected by panTLE antibody that recog-
nized the entire TLE family [23], whereas our study
showed that TLE3 was down-regulated in CRC. In
addition, previous studies have showed hyper-methylation
of TLE3 [25] and overexpression of TLE4 in CRC [43].
Taken together, we inferred that it was TLE4, TLE1 and
TLE2 but not TLE3 that were overexpressed in colonic
adenocarcinoma. The multiple properties of TLE family
were explained by context-dependent characteristics [17],
but the underlying mechanism remains largely unknown
and emerge great potential in cancer research.
As an element of Notch signaling that regulates cell
fate determination, TLE3 participates in cell differenti-
ation under physiological circumstance [21, 47–51]. As
for CRC cancer, we observed that TLE3 could cause the
G1-S phase transition arrest in a certain extent and repress
the growth and proliferation of CRC. Both p21 and p27
have been identified as mediators of tumor suppression
through G1 or G2 arrest, involving binding to CyclinA/
cyclin-dependent kinase (CDK) 2, CyclinE/CDK2, and
CyclinD/CDK4/6 complexes [35, 36, 52]. Loss of p21
and p27 could enhance tumorigenesis [53]. Further
studies have revealed that Ras/MAPK and PI3K/AKT
signaling were closely associated with p21 and p27. On
the one hand, Ras/MAPK and PI3K/AKT signaling play
vital roles in proliferation partly via the regulation of
cyclinD1 and CDK inhibitors including p21 and p27
[54–56]. The ubiquitylation-dependent proteasomal
degradation of p21 and p27 is mediated by Ras/MAPK
and PI3K/AKT signaling [57]. On the other hand,
p27Kip1 promoter could be activated by the FOXO
family (FOXO4, FOXO3a, and FOXO1), whose activity
was modulated by Ras/MAPK and PI3K/AKT pathways
[58–60]. Moreover, Gro is a junction of Ras-associated
network of multiple signaling cascades, which could
attenuate the Gro-dependent repression [17, 61]. Here,
we showed that p-ERK, p-GSK and p-AKT were down-
regulated by TLE3, indicating the suppressor role of
TLE3 in MAPK and PI3K/AKT pathways. Correspond-
ingly, p21 and p27 protein expression were up-
regulated by TLE3. In addition, TLE3 enhanced the
transcription of p21 and p27, which could be explained
by the contribution of FOXO3a.
Conclusions
Collectively, our study uncovered another novel aspect
of TLE3 in the progression of CRC. Lower expression of
TLE3 was closely associated with more advanced CRC
progression and poorer outcome of patients with CRC,
while overexpression of TLE3 suppressed CRC prolifera-
tion both in vitro and in vivo. Furthermore, TLE3 could
cause G1-S phase transition arrest by increasing the
expression of p21 and p27, the underlying mechanism of
which was TLE3-mediated inhibition of MAPK and
AKT signaling pathways. These findings indicate the
potential of TLE3 as a biomarker for CRC prognosis.
However, the detailed mechanism of TLE3 in CRC pro-
gression needs further investigations.
Additional files
Additional file 1: Table S1. Primer Sequences used for RT-qPCR (5’ to 3’).
(DOCX 13 kb)
Additional file 2: Figure S1. Gene set enrichment analyses of TLE3
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